Press Release
Shattuck Labs to Present Two Posters at the 2021 American Association for Cancer Research (AACR) Annual Meeting
Presentation Details
Title: Antigen-specific targeting of tissue-resident gamma delta T cells with recombinant butyrophilin heterodimeric fusion proteins
Presenter: Dr.
Virtual Session Date: April 10-15, 2021
Virtual Session Location: E-Poster Session
Abstract Number: 1736
Title: The development of an in vivo model of checkpoint acquired resistance, reveals a program of interferon hyperstimulation, resulting in dysregulation of MHC class I, protein translation/trafficking, and other unique pathways, that may be useful for guiding clinical strategy in patients with phenotypic similarities
Presenter: Dr.
Virtual Session Date: April 10-15, 2021
Virtual Session Location: E-Poster Session
Abstract Number: 1697
Additional meeting information can be found on the AACR website, https://www.aacr.org. The posters will be available under the Events & Presentations section of the Company’s website shortly after the event.
About
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with
Investor Contact:
Senior Director, Finance & Investor Relations
InvestorRelations@shattucklabs.com
Media Contact:
Managing Director
Stern Investor Relations, Inc.
Stephanie.Ascher@sternir.com
Source: Shattuck Labs, Inc.